JNJ-47965567


CAS No. : 1428327-31-4

1428327-31-4
Price and Availability of CAS No. : 1428327-31-4
Size Price Stock
5mg $100 In-stock
10mg $195 In-stock
25mg $320 In-stock
50mg $512 In-stock
100 mg Get quote
200 mg Get quote
We match the lowest price on market.

We offer a substantial discount on larger orders, please inquire via [email protected]

or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Cat. No. : HY-101418
M.Wt: 488.64
Formula: C28H32N4O2S
Purity: >98 %
Solubility: DMSO : 100 mg/mL (204.65 mM; Need ultrasonic)
Introduction of 1428327-31-4 :

JNJ-47965567 is a centrally permeable, high-affinity, selective P2X7 antagonist, with pKis of 7.9 and 8.7 for human and rat P2X7, respectively. JNJ-47965567 can be used to probe the role of central P2X7 in rodent models of CNS pathophysiology[1]. IC50 & Target: pKi: 7.9 (huaman P2X7), 8.7 (rat P2X7)[1] In Vitro: JNJ-47965567 exhibits high affinity for human and rat P2X7 in membrane preparations of 1321N1 cells[1].
JNJ-47965567 does not block IL-6 and TNF-α release, under identical conditions (LPS and BZ-ATP) used for IL-1β and IL-18 release[1].
JNJ-47965567 attenuates IL-1β release with pIC50s of 6.7 ± 0.07 (human blood), 7.5 ± 0.07 (human monocytes) and 7.1 ± 0.1 (rat microglia), respectively, in native systems[1].
In Vivo: JNJ-47965567 (30-100 mg/kg; s.c.) attenuates IL-1β release induced by Bz-ATP[1].
JNJ-47965567 (30 mg/kg) attenuates amphetamine-induced hyperactivity and exhibits modest, yet significant efficacy in the rat model of neuropathic pain[1].

Your information is safe with us.